12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AV-203: Phase I started

Aveo began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV AV-203 every 2 weeks in up to 30 patients with metastatic or advanced solid tumors. The company will also enroll up to 60 patients...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >